Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747)

M. Elkabets, S. Vora, D. Juric, N. Morse, M. Mino-Kenudson, T. Muranen, J. Tao, A. B. Campos, J. Rodon, Y. H. Ibrahim, V. Serra, V. Rodrik-Outmezguine, S. Hazra, S. Singh, P. Kim, C. Quadt, M. Liu, A. Huang, N. Rosen, J. A. EngelmanM. Scaltriti, J. Baselga

Research output: Contribution to journalComment/debate

Abstract

In the Research Article "mTORC1 Inhibition Is Required for Sensitivity to PI3K p110á Inhibitors in PIK3CA-Mutant Breast Cancer," the authors have provided additional competing interests upon request by the editors, and the competing interests statements have been updated. The PDF and HTML (full text) have been corrected.

Original languageEnglish
Article numbereaav9425
JournalScience Translational Medicine
Volume10
Issue number468
DOIs
StatePublished - 14 Nov 2018

ASJC Scopus subject areas

  • Medicine (all)

Fingerprint

Dive into the research topics of 'Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747)'. Together they form a unique fingerprint.

Cite this